[Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study].

Magyar onkologia Pub Date : 2024-12-10 Epub Date: 2024-11-20

Andrea Kohánka, László Báthory-Fülöp, Eszter Tanács-Bencze, Helga Engi, Krisztina Bogos, Judit Moldvay, Zsolt Székely Pápai, Zsuzsanna Szalai, János Szőke, Erika Tóth

{"title":"[Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study].","authors":"Andrea Kohánka, László Báthory-Fülöp, Eszter Tanács-Bencze, Helga Engi, Krisztina Bogos, Judit Moldvay, Zsolt Székely Pápai, Zsuzsanna Szalai, János Szőke, Erika Tóth","doi":"","DOIUrl":null,"url":null,"abstract":"Aim: In our institute, we have been testing EGFR T790M resistance mutations since 2019, which is the most common resistance mutation that develops during first-line, second- line EGFR TKI treatment of EGFR mutant lung adenocarcinomas. The importance of this study is that the identification of this mutation will allow the use of an effective third-generation TKI. In this article, we report on studies from January 2022 to August 2024, compared with our results from the 2019-2021 period.Methods: 380, predominantly blood samples from 222 patients were tested during the present period using Super- ARMS EGFR Mutation Detection Kit (AmoyDx).Results: EGFR mutations were identified in 57% of all samples in the primary tumours, with a 38.3% frequency of T790M mutation.Conclusions: Our results were similar to the previous period. The number of rebiopsies was essentially unchanged compared to the 2019-2021 period, which may be the main reason why we were able to identify the mutation in a lower percentage compared to the T790M hit rate described in the literature.","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 4","pages":"334"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Magyar onkologia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: In our institute, we have been testing EGFR T790M resistance mutations since 2019, which is the most common resistance mutation that develops during first-line, second- line EGFR TKI treatment of EGFR mutant lung adenocarcinomas. The importance of this study is that the identification of this mutation will allow the use of an effective third-generation TKI. In this article, we report on studies from January 2022 to August 2024, compared with our results from the 2019-2021 period.

Methods: 380, predominantly blood samples from 222 patients were tested during the present period using Super- ARMS EGFR Mutation Detection Kit (AmoyDx).

Results: EGFR mutations were identified in 57% of all samples in the primary tumours, with a 38.3% frequency of T790M mutation.

Conclusions: Our results were similar to the previous period. The number of rebiopsies was essentially unchanged compared to the 2019-2021 period, which may be the main reason why we were able to identify the mutation in a lower percentage compared to the T790M hit rate described in the literature.

本刊更多论文

[肺腺癌分子病理学，表皮生长因子受体 T790M 抗性突变研究]。

目的：我院自2019年起开始检测表皮生长因子受体T790M耐药突变，这是表皮生长因子受体突变肺腺癌一线、二线EGFR TKI治疗过程中最常见的耐药突变。这项研究的重要性在于，该突变的确定将使第三代TKI的有效使用成为可能。在本文中，我们报告了2022年1月至2024年8月的研究情况，并与2019-2021年的研究结果进行了对比。方法：在此期间，我们使用Super- ARMS EGFR突变检测试剂盒（AmoyDx）检测了222名患者的380份血液样本，其中主要是血液样本：结果：57%的原发性肿瘤样本中发现了表皮生长因子受体突变，其中T790M突变频率为38.3%：结论：我们的研究结果与前一时期相似。与2019-2021年期间相比，重新检查的数量基本没有变化，这可能是我们能够识别出的突变比例低于文献中描述的T790M命中率的主要原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Magyar onkologia

自引率

0.00%

发文量